Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. rhyp

RHYP SIGNED

A new hope for early gonarthrosis treatment using a biotechnological therapeutic drug to regenerate cartilage by intra-articular knee injection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 RHYP project word cloud

Explore the words cloud of the RHYP project. It provides you a very rough idea of what is the project "RHYP" about.

hyaluronic    reg    first    world    clinical    o3    mode    symptomatic    treatment    mrd    2017    successful    2016    restore    partnership    commercialization    trials    economic    countries    rhyp    drug    athletes    curative    painless    injection    conditioning    trial    plug    ambition    treatments    75    price    younger    obese    progression    ga    450    function    licensees    contribution    slow    market    previously    launching    health    viscosupplementation    articulation    pushing    requested    acid    vitro    stage    proof    candidate    manufacturing    joint    thanks    local    activation    feasibility    human    knee    replacement    burden    drawback    people    stop    administration    ec    suffer    global    competitive    surgery    total    responding    moderate    cartilage    03    therapeutic    action    gmp    months    24    vivo    gonarthrosis    mainly    social    clinics    sustain    tackle    disease    degenerative    molecules    batch    disruptive    syringes    smeinst    gap    trl    conduct    worldwide    huge    instrument    prepare    chondrocytes    organization    2014    degradation    sme    50    proliferation    5   

Project "RHYP" data sheet

The following table provides information about the project.

Coordinator		 REGULAXIS 

Organization address
address: 102 AVENUE GASTON ROUSSEL
city: ROMAINVILLE
postcode: 93230
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://regulaxis.com/
 Total cost 3˙008˙500 €
 EC max contribution 2˙105˙950 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2020-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGULAXIS FR (ROMAINVILLE) coordinator 2˙105˙950.00

Map

 Project objective

The aim of RHYP is to sustain the commercialization of a new promising therapeutic product (REG-O3) to restore the joint function for the treatment of early and moderate gonarthrosis (GA). GA is a degenerative knee joint disease that represents a huge social and economic burden worldwide. According to the World Health Organization, more than 5% of people over 40 and 50% of people over 75 years suffer specifically from GA in developed countries. It affects also a growing number of younger people as athletes and obese people, among others. There are currently no therapeutic molecules on the market for the treatment of early GA to slow down or stop disease progression and avoid surgery joint replacement. Available treatments for this disease stage are mainly symptomatic, such as the widely use injection of hyaluronic acid (HA) in articulation (viscosupplementation – Global market €1.5 Mrd in 2014). RHYP’s ambition is to tackle this current drawback by pushing forward its drug candidate REG-O3 into clinics to propose a disruptive and long-term treatment (curative and symptomatic action) using a painless local administration mode at a competitive price (€450 for total treatment is estimated). The selected lead REG-O3 activity proof of concept on chondrocytes proliferation activation to slow down cartilage degradation was previously established in vitro and in vivo. Following successful feasibility studies conducted thanks to the European commission (EC) through the Phase 1 of the SME Instrument, RHYP is now responding to the topic “SMEInst-03-2016-2017” in phase 2. RHYP is now aiming, during this 24 months’ project with a EC requested contribution of €2,1 M, to plug the gap from TRL 6 to TRL 9 by launching REG-O3 GMP batch manufacturing and syringes conditioning to conduct First-in-Human clinical trial. The project objective is also to prepare future partnership with identified potential licensees to conduct Clinical trials in Phase III and drug commercialization.

 Deliverables

List of deliverables.
Ethical protocols reports and authorization approval copies Documents, reports 2020-04-16 13:45:11
Report to present RHYP corporate identity and first leaflet and promotion material models Documents, reports 2020-01-21 15:58:55

Take a look to the deliverables list in detail:  detailed list of RHYP deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RHYP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RHYP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

IcoCell (2015)

IcoCell− Chassis for Enhanced Mammalian Cell Line Development and Engineering

Read More  

TYCHOBIO (2017)

Commercialization of high-value chemical production in moss

Read More